Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Spero Therapeutics (SPRO) Stock Price & Analysis

604 Followers

SPRO Stock Chart & Stats

$1.02$0.01(0.99%)
At close: 4:00 PM EST
$1$1.1$1.2$1.3Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.01 - $1.05
52-Week Range
$0.96 - $3.08
Previous Close
$1.01
Volume
N/A
Average Volume (3M)
420.99K
Market Cap
$58.82M
Enterprise Value
$79.38M
Total Cash (Recent Filing)
$50.77M
Total Debt (Recent Filing)
$2.04M
Price to Earnings (P/E)
7.3
Beta
1.79
Next Earnings
Nov 16, 2026 (Est.)
EPS Estimate
-0.47
Last Dividend Ex-Date
Sep 16, 2015
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Approved Utebzi With GSK Commercialization

Utebzi approval converts a key antibiotic program into a commercial opportunity, while GSK’s exclusive rights provide an experienced commercialization partner. Expected U.S. availability in 2H 2026 creates a durable pathway to milestone and royalty income.

Extended Funding Runway

The nondilutive financing materially extends Spero’s operating runway without immediate equity issuance, supporting continued development and strategic execution. Funding visibility through 2H 2029 reduces near-term liquidity pressure and allows management to pursue milestones from a stronger position.

Conservatively Levered Balance Sheet

Very low debt relative to equity limits balance-sheet risk and preserves financial flexibility as Spero advances its pipeline. Positive return on equity indicates that recent profitability has not depended heavily on leverage, supporting greater resilience across funding and development cycles.

Bears Say

Revenue Interruption And Wider Quarterly Loss

The sharp quarterly revenue decline and wider loss show that reported financial performance remains highly dependent on collaboration revenue and milestone timing. Until recurring commercial or royalty receipts develop, earnings visibility and the durability of current profitability remain uncertain.

Dependence On Utebzi Royalty Streams

Although the financing is nonrecourse, its principal and interest payments depend on Utebzi’s future commercial performance and milestone generation. The 10% annual rate also creates a substantial fixed claim on proceeds, increasing execution sensitivity around launch and demand.

Unproven Early-stage SP001 Program

SP001 offers strategic pipeline potential but remains clinically unproven, with a small planned Phase II study that may provide limited evidence of efficacy or durability. Realizing its contingent value will require successful trials, regulatory progress, and effective commercial execution.

Spero Therapeutics News

SPRO FAQ

What was Spero Therapeutics’s price range in the past 12 months?
Spero Therapeutics lowest stock price was $0.96 and its highest was $3.08 in the past 12 months.
What is Spero Therapeutics’s market cap?
Spero Therapeutics’s market cap is $58.82M.
When is Spero Therapeutics’s upcoming earnings report date?
Spero Therapeutics’s next earnings report is estimated for Nov 16, 2026 (not yet confirmed), which is in 4 days.
How were Spero Therapeutics’s earnings last quarter?
Spero Therapeutics released its earnings results on Aug 12, 2026. The company reported -$0.16 earnings per share for the quarter.
Is Spero Therapeutics overvalued?
According to Wall Street analysts Spero Therapeutics’s price is currently Undervalued.
Does Spero Therapeutics pay dividends?
Spero Therapeutics pays a quarterly dividend of $0.015 which represents an annual dividend yield of ―. See more information on Spero Therapeutics dividends here
What is Spero Therapeutics’s EPS estimate?
Spero Therapeutics’s EPS estimate is -0.47.
How many shares outstanding does Spero Therapeutics have?
Spero Therapeutics has 58,234,825 shares outstanding.
What happened to Spero Therapeutics’s price movement after its last earnings report?
Spero Therapeutics reported an EPS of -$0.16 in its last earnings report. Following the earnings report the stock price went up 4.202%.
Which hedge fund is a major shareholder of Spero Therapeutics?
Hedge funds hold Spero Therapeutics shares: the largest hedge-fund position in Spero Therapeutics is 71,886,630 shares, and hedge funds decreased their holdings by 260.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology